---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012325"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-08-26T23:59:59+00:00"
generated_at: "2026-05-17T09:56:15.209712+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lipocine announces LPCN 2101 abstracts accepted for AES 2025 annual meeting

## Summary
- Two LPCN 2101 abstracts accepted for poster presentation at AES 2025 (Dec 5-9, Atlanta).
- Abstracts cover oral toxicokinetics and clinical pharmacokinetics/tolerability of LPCN 2101.
- LPCN 2101 is a GABA-A receptor modulating neuroactive steroid for potential treatment of epilepsy.
- Data remain embargoed until November 24, 2025, per AES policy.

## SEC filing metadata
- accession: 0001493152-25-012325
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225012325/0001493152-25-012325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225012325/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012325
- JSON: https://secwatch.observer/filing/0001493152-25-012325.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012325.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.